Politi Jason 4

4 · Verve Therapeutics, Inc. · Filed Apr 3, 2025

Form 4

Period: 2025-04-01

Chief Technical Ops. Off.

Transactions

Exercise/Conversion
Common Stock
2025-04-01+8,815→ 17,461 total
Sale
Common Stock
2025-04-02$4.15/sh−3,235$13,425→ 14,226 total
Exercise/Conversion
Restricted Stock Units
2025-04-01−3,315→ 6,630 total
→ Common Stock (3,315 underlying)
Exercise/Conversion
Restricted Stock Units
2025-04-01−5,500→ 16,500 total
→ Common Stock (5,500 underlying)

Footnotes (5)

[F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
[F2]Includes 2,380 shares of the Company's common stock acquired in 2024 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
[F3]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 29, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
[F4]On February 14, 2023, the reporting person was granted 13,260 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2024 and the remainder vesting in equal annual installments until April 1, 2027.
[F5]On February 14, 2024, the reporting person was granted 22,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028.

Documents

1 file